Warning: Declaration of subscribe2_widget::addPluginSubMenu() should be compatible with mijnpress_plugin_framework::addPluginSubMenu($title, $function, $file, $capability = 10, $where = 'plugins.ph...') in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18

Warning: Declaration of subscribe2_widget::addPluginContent($links, $file) should be compatible with mijnpress_plugin_framework::addPluginContent($filename, $links, $file, $config_url = NULL) in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18
Regional Venture News | SEBIO

VeriTeQ Corporation Secures Financing

Posted by on Nov 15, 2013 in Newsroom, Regional Venture News | 0 comments

DELRAY BEACH, FL. – VeriTeQ Corporation (“VeriTeQ” or the “Company”, f/k/a Digital Angel Corporation) (OTC Markets: DIGAD), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has completed a multi-tranche financing totaling $1,500,000 of gross proceeds, with the initial investment amount of $750,000 expected to fund on or around November 13, 2013. The financing is structured as a convertible note and warrants to purchase shares of VeriTeQ’s common stock. On November 13, 2013, the Company entered into a...

Read More

Envisia Therapeutics Debuts with $25 Million Series A Financing

Posted by on Nov 13, 2013 in Newsroom, Regional Venture News | 0 comments

RESEARCH TRIANGLE PARK, N.C. – Envisia Therapeutics, a new biotechnology company formed by Liquidia Technologies, today announced the Company’s debut, which is backed by $25 million in Series A financing. Envisia will focus on addressing unmet medical needs in various areas of ophthalmology. Envisia’s lead product, ENV515, is an extended-release formulation of a prostaglandin analogue. ENV515 has the potential to offer glaucoma patients an innovative product that can provide a sustained reduction in intraocular pressure (IOP) over many months after single administration. “With...

Read More

Salix Pharmaceuticals to Acquire Santarus

Posted by on Nov 8, 2013 in Newsroom, Regional Venture News | 0 comments

RALEIGH, NC and SAN DIEGO, CA – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Santarus, Inc. (NASDAQ:SNTS) today announced that the companies have entered into a definitive merger agreement under which Salix will acquire all of the outstanding common stock of Santarus for $32.00 per share in cash (without interest). The all-cash transaction values Santarus at approximately $2.6 billion. The $32.00 per share price represents an approximately 36% premium over Santarus’ November 6, 2013 closing price of $23.53 per share and an approximately 39% premium over Santarus’ average closing...

Read More

Morphogenesis Inc. Announces Plans for $2 Million Private Offering

Posted by on Nov 7, 2013 in Newsroom, Regional Venture News | 0 comments

TAMPA, FL – Morphogenesis Inc., a Florida corporation with headquarters in Tampa, FL, announces its plans to raise up to $2 million from the sale of its common stock to accredited investors. The company’s Private Placement Memorandum is expected to be available for review later this month. Morphogenesis Inc. (www.morphogenesis-inc.com) is an 18-year-old, privately-held biotechnology company which conducts ground-breaking research in the rapidly growing cell therapy, biologics and tissue engineering fields. Morphogenesis has developed, and is primarily focused on, its multi-indication...

Read More

ADial Pharmaceuticals Announces Strategic Partnership With Cato BioVentures

Posted by on Nov 4, 2013 in Newsroom, Regional Venture News | 0 comments

CHARLOTTESVILLE, VA,– ADial Pharmaceuticals (ADial) announced that it has entered into a strategic partnership with Cato BioVentures. Under the terms of the agreement, Cato BioVentures will invest up to $1.8 million in ADial, and Cato Research, an affiliate of Cato BioVentures, will serve as the preferred contract research organization for ADial’s clinical trials of AD04, ADial’s drug for the treatment of alcohol addiction in patients with selected genotypes. “This partnership provides ADial with the expertise and world-class capabilities of the Cato team,” said...

Read More

Nanotherapeutics, Plans $122 Million Expansion In Alachua, Florida

Posted by on Oct 24, 2013 in Newsroom, Regional Venture News | 0 comments

ALACHUA, FL – Nanotherapeutics, Inc., will invest $122 million to expand its campus in Alachua, Florida, creating 150 jobs at its new manufacturing facility. Headquartered in Alachua and operating in Progress Corporate Park, Nanotherapeutics began as a start-up at University of Florida’s Sid Martin Biotechnology Incubator. Nanotherapeutics will integrate into a new state-of-the-art facility with flexible, single use, disposable equipment that can provide the military’s national security requirements for Medical Counter Measures. “Florida’s life science sector continues to...

Read More